Metoprolol in Acute Myocardial Infarction. A PK/PD Study
NCT ID: NCT01523054
Last Updated: 2012-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
27 participants
INTERVENTIONAL
2000-02-29
2002-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Pharmacokinetics, peak and trough plasma concentrations and area under the plasma concentration curve.
Pharmacodynamics, hourly means of Holter recorded heart rate. Tolerability. An open, randomised design with two parallel groups was employed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The METOCARD-CNIC Trial.
NCT01311700
Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients
NCT03579914
The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.
NCT03532802
Pain Relief of Metoprolol Versus Metoprolol Plus Morphine in Acute Chest Pain
NCT00718406
Effect of BMS-914392 on Pharmacokinetics of Metoprolol
NCT01211821
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metoprolol- Toprol XL
Metoprolol extended release (CR/XL) tablet 200 mg once daily
Metoprolol- Toprol XL
Extended release tablet, 200mg once daily for 4 days
Metoprolol- Lopressor
Metoprolol immediate release (IR) tablet
Metoprolol- Lopressor
Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metoprolol- Toprol XL
Extended release tablet, 200mg once daily for 4 days
Metoprolol- Lopressor
Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 years or older
* Treated with and tolerated the full dose of metoprolol IR 50 mr four times daily or metoprolol CR/XL 200 mg once daily on study day 1
* Expected to stay in the CCU until the morning of study day 4
* Sinus rhythm on the day of admission and at randomisation
Exclusion Criteria
* Participation in a clinical study during the last 30 days or previous randomisation in the present study
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dag Elmfeldt, MD, PHD
Role: STUDY_DIRECTOR
AstraZeneca R&D Mölndal
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SH-MET-0027
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.